...
首页> 外文期刊>Nature photonics >Blood-vessel closure using photosensitizers engineered for two-photon excitation
【24h】

Blood-vessel closure using photosensitizers engineered for two-photon excitation

机译:使用为双光子激发而设计的光敏剂封闭血管

获取原文
获取原文并翻译 | 示例
           

摘要

The spatial control of optical absorption provided by two-photon excitation has led to tremendous advances in microscopy(1) and microfabrication(2). Medical applications of two-photon excitation in photodynamic therapy(3,4) have been widely suggested(5-18), but thus far have been rendered impractical by the low two-photon cross-sections of photosensitizer drugs (which are compounds taken up by living tissues that become toxic on absorption of light). The invention of efficient two-photon activated drugs will allow precise three-dimensional manipulation of treatment volumes, providing a level of targeting unattainable with current therapeutic techniques. Here we present a new family of photodynamic therapy drugs designed for efficient two-photon excitation and use one of them to demonstrate selective closure of blood vessels through two-photon excitation photodynamic therapy in vivo. These conjugated porphyrin dimers have two-photon cross-sections that are more than two orders of magnitude greater than those of standard clinical photosensitizers(17). This is the first demonstration of in vivo photodynamic therapy using a photosensitizer engineered for efficient two-photon excitation.
机译:由双光子激发提供的光吸收的空间控制导致了显微镜(1)和微加工(2)的巨大进步。广泛建议在光动力疗法中将双光子激发的医学应用(3,4)(5-18),但到目前为止,由于光敏剂药物的低双光子截面(已被吸收的化合物)变得不切实际。通过对光的吸收有毒的活组织)。有效的双光子活化药物的发明将允许对治疗量进行精确的三维操纵,从而提供当前治疗技术无法达到的靶向水平。在这里,我们介绍了一个新的光动力疗法药物家族,旨在有效地激发两光子,并使用其中一种来证明通过体内的两光子激发光动力疗法选择性关闭血管。这些共轭的卟啉二聚体具有两个光子截面,比标准临床光敏剂的截面大两个数量级以上(17)。这是使用光敏剂进行体内光动力疗法的首次演示,该光敏剂经过工程设计,可实现高效的双光子激发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号